6 research outputs found
Adverse events in all cycles of treatment for all patients receiving at least one cycle of treatment in the CSV and MSV groups.
<p>Adverse events in all cycles of treatment for all patients receiving at least one cycle of treatment in the CSV and MSV groups.</p
Dose Escalation Schedule for the CSV and MSV arms.
<p>Dose Escalation Schedule for the CSV and MSV arms.</p
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules - Fig 3
<p>Mean plasma concentration-time curves of erlotinib (A) on Day 3 after initial oral dose with CSV dosing regimen of vinorelbine, (B) on Day 10 at the steady state after oral dose with CSV dosing regimen of vinorelbine, (C) on Day 3 after initial oral dose with MSV dosing regimen of vinorelbine and (D) on Day 10 at the steady state after oral dose with MSV dosing regimen of vinorelbine.</p
Patient demographics and baseline characteristics.
<p>Patient demographics and baseline characteristics.</p